AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06544733
Drug: Placebo to Match BVY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally without regard to food
Trial: NCT06544733
Drug: GS-1720/GS-4182 FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally without regard to food
Trial: NCT06544733
Drug: Placebo to Match GS1720/GS-4182 FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally without regard to food
Trial: NCT05799521
Drug: Optate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alkaline Buffer
Trial: NCT05799521
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline
Trial: NCT05029635
Drug: HMPL-523
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMPL-523 will be oral administrated once daily for 24 weeks
Trial: NCT05029635
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMPL-523 matching placebo will be oral administrated once daily for 24 weeks .
Trial: NCT05248386
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching RTX-GRT7039 intra-articular injection.
Trial: NCT05056727
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powder for oral suspension in a sachet. Placebo to match 5 or 10 g. Single dose will consist of 1-3 sachets.~During Maintenance Phase:~- Single dose contains 5 g placebo administered every other day or 5, 10, or 15 g placebo administered once daily that should be suspended in 45 mL of water.
Trial: NCT05972655
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine: 1000mg/m2 d1-14 q3w
Trial: NCT06408688
Drug: Immune checkpoint inhibitors plus Iscador® Qu.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard cancer treatment plus subcutaneous injection of mistletoe fermented extract (Iscador® Qu) as per the summary of product characteristics.
Trial: NCT05869383
Drug: Ophiochepalus striatus extract
RxNorm normalized name: Bletilla striata bulb extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophiochepalus striatus extract 2x5 grams
Trial: NCT05869383
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 2x5 grams
Trial: NCT05587478
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match EDP-323, oral administration
Trial: NCT06541535
Drug: Fluid resuscitation with Ringer Lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer Lactate only will be used for fluid resuscitation in the first 48 hours of treatment, according to the protocol of English guidelines:~* During the first hour of treatment:~  * In the event of systolic arterial hypotension (SAP\<90mmHg): administration of 500 mL over 15 minutes, renewable once, then administration of 1L over 1 hour.~ * In the absence of systolic arterial hypotension (SAP\>90mmHg): administration of 1L over 1 hour.~* Between 60 minutes and 8 hours of treatment :~  * 1L over 2 hours, repeated once, then 1L over 4 hours~ * Adjust fluid resuscitation according to clinical tolerance~* After the first 8 hours:~  * 1L over 4h then 1L over 6h~ * Clinical re-evaluation according to standard of care in participating centers
Trial: NCT05253105
Drug: TAB006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant humanized, IgG4κ (immunoglobulin gamma 4, kappa) monoclonal antibody (mAb) that specifically binds to the T cell immunoreceptor with Ig and ITIM domains (TIGIT))
Trial: NCT05466448
Drug: RZL-012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: concentration of injected formulation 50 mg/mL RZL-012 of 7.5 mg/0.15 mL/injection point that results in a maximum total dose/volume of 240±30 mg/4.8±0.6 mL RZL-012
Trial: NCT06255210
Drug: Gemcitabine+Cisplatin(GP); Cyclophosphamide+Etoposide+Cisplatin(CEP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: When the Ki67% index of the tumor is ≥ 25%, patients were treated with the GP regimen for induction chemotherapy; When the Ki67% index of the tumor is \< 25%, patients were treated with the CEP regimen for induction chemotherapy.
Trial: NCT05474378
Drug: B7-H3CART
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B7-H3CART will be administered administered locoregionally (either ICV or both ICV and intratumorally (IT)) at one of the following doses:~Dose Level -1: 5 x 10\^6 CAR+ cells (+/- 20%) Dose Level 1: 10 x 10\^6 CAR+ cells (+/- 20%) Dose Level 2: 25 x 10\^6 CAR+ cells (+/- 20%) Dose Level 3: 50 x 10\^6 CAR+ cells (+/- 20%) Dose Level 4: 100 x 10\^6 CAR+ cells (+/- 20%)~B7-H3CART Dose Dose Level -1 (DL-1): 5 x 106 B7-H3CART+ cells (± 20%) Dose Level 1 (DL 1): 10 x 106 B7-H3CART+ cells (± 20%) Dose Level 2 (DL2): 25 x 106 B7-H3CART+ cells (± 20%) Dose Level 3 (DL3): 50 x 106 B7-H3CART+ cells (± 20%) Dose Level 4 (DL4): 100 x 106 B7-H3CART+ cells (± 20%)~Repeated every 28 days (-7 / +14 days) as long as infusion criteria are met for a total of 6 doses, with an option for an additional 6 doses, up to a total of 12.
Trial: NCT06134271
Drug: Continue previous treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue using the previous treatment regimen for treatment.
Trial: NCT05262959
Drug: Donafenib, PD-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible subjects will receive Donafenib combined with PD-1 and TACE. Donafenib will be taken orally twice a day, 0.1mg each time.PD-1 will be used intravenously every 3 weeks.
Trial: NCT05256745
Drug: TTP488
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each Azeliragon capsule is 5mg, and is to be taken in the morning with food as indicated in each cohort.
Trial: NCT05256745
Drug: TC
RxNorm normalized name: PTC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel plus cyclophosphamide (TC) for 4-6 cycles, administered per USPI (Unites States Prescribing Information) Label
Trial: NCT05256745
Drug: Chemotherapy regimen that includes ddAC
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: can include: (1) weekly carboplatin + paclitaxel + pembrolizumab followed by pembrolizumab + dose dense doxorubicin and cyclophosphamide; (2) weekly carboplatin + paclitaxel followed by dose dense doxorubicin and cyclophosphamide; (3) weekly or dose dense paclitaxel followed by dose dense doxorubicin and cyclophosphamide, administered per USPI (Unites States Prescribing Information) Label
Trial: NCT05759754
Drug: TCM+ Routine Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Gu Shen Juan Yu Formula contains 11 herbs and it is available in liquid form for patients. Patients will receive Gu Shen Juan Yu Formula, 3g or 6g or 12g each time based on weight (3g for W≤20kg, 6g for 20-30kg, or 12g for W\>30kg), 2 times a day for 12 weeks, orally.~Routine therapy: Patients receiving a stable dose of ACEI/ARB will be continued.
Trial: NCT05759754
Drug: Routine Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive a stable dose of ACEI/ARB drug as a routine therapy.
Trial: NCT05184478
Drug: Medicinal cannabis (MC): THC 10mg/mL : CBD 15mg/mL, manufactured by Cann Group Ltd.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each 1mL contains 10mg tetrahydrocannabinol (THC),15 mg cannabidiol (CBD), and 0.004mL peppermint oil in medium chain triglyceride (MCT) oil.~All participants will start at 0.1 mL per day, and will gradually increase in 0.1mL increments until day 21 when a dose of 0.5mL (participants weighing \<50kg) or 1mL (participants weighing ≥50kg) is reached. At day 29, an assessment of treatment response will be conducted. Participants who meet criteria for a treatment response will remain on the same dose for the remainder of the treatment period. Participants who do not meet criteria for a treatment response will gradually increase the dose in 0.1mL increments until day 49 when a daily dose of 1mL (participants weighing \<50kg) or 2mL (participants ≥50kg) is reached.
Trial: NCT05184478
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo contains MCT oil and peppermint flavoring solution, which is indistinguishable from the active medication in appearance, smell and taste.~The dose will be matched for volume to the medicinal cannabis, and will follow the same dosing schedule as the medicinal cannabis treatment phase.
Trial: NCT06705062
Drug: Standard dose PTCY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receiving standard dose PTCy at 50mg/kg on day +3 and +4 with tacrolimus starting from day +5 and single dose of anti-thymoglobin at 2.5mg/kg 72 hours after documentation of neutrophil engraftment.
Trial: NCT05277922
Drug: C21
RxNorm normalized name: C18-C21 alkane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C21 in ascending doses of 15, 50, 150, 500 and 1000 µg
Trial: NCT05728944
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proprietary vehicle ophthalmic solution
Trial: NCT06287606
Drug: CTP0302-A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized into group CTP0302-A will take a bowel preparation from the evening until the following morning.
Trial: NCT06287606
Drug: CTP0302-B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized into group CTP0302-B will take a bowel preparation on the Colonoscopy day
Trial: NCT05627557
Drug: Acetaminophen/ Paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 15 mg/kg (maximum dose 1000 mg) will be administered PO as premedication prior to infusions.
Trial: NCT05035485
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A rescue norepinephrine (6μg) was given when postspinal anesthesia hypotension occurred within 30 minutes after spinal anesthesia
Trial: NCT05019521
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet.
Trial: NCT05869474
Drug: Gem/nab-P Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nab-paclitaxel (125 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter) on days 1, 8 every 3 weeks
Trial: NCT05521269
Drug: ANX1502
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANX1502 is a prodrug of ANX1439.
Trial: NCT05521269
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator.
Trial: NCT06254950
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-279 placebo-matching capsules.
Trial: NCT06074497
Drug: KGX101- Cohort -1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 0.1, 0.3, 1μg/kg of KGX101 every 3 weeks
Trial: NCT06074497
Drug: KGX101- Cohort 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 0.3, 1.0, 3.0μg/kg of KGX101 every 3 weeks
Trial: NCT06074497
Drug: KGX101- Cohort 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 1, 1 and 3μg/kg of KGX101 every 3 weeks
Trial: NCT06074497
Drug: KGX101- Cohort 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 1,3 and 6μg/kg of KGX101 every 3 weeks
Trial: NCT06074497
Drug: KGX101- Cohort 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 1,3,12μg/kg of KGX101 every 3 weeks
Trial: NCT06074497
Drug: KGX101- Cohort 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 2, 5 and 15 μg/kg of KGX101 every 3 weeks
Trial: NCT05482893
Drug: KEYTRUDA® (pembrolizumab)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune checkpoint inhibitor as a combination partner to Spevatamig (PT886) in Part D: Cohort 3, 4, and 5.
Trial: NCT05482893
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy as a combination partner to KEYTRUDA® (pembrolizumab) and Spevatamig (PT886) in Part D: Cohort 4
Trial: NCT05482893
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy as a combination partner to KEYTRUDA® (pembrolizumab) and Spevatamig (PT886) in Part D: Cohort 4
Trial: NCT05482893
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy as a combination partner to KEYTRUDA® (pembrolizumab) and Spevatamig (PT886) in Part D: Cohort 4
Trial: NCT05482893
Drug: FOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy as a combination partner to Spevatamig (PT886) in Part C: Cohort 2b
Trial: NCT06072586
Drug: BDTX-1535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDTX-1535 is an inhibitor of EGFR mutations
Trial: NCT04821817
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: peribulbar anesthesia with 10 ml local anesthetic mixture composed of 4 ml of plain bupivacaine 0.5%, 4 ml of lidocaine 2% containing 50 IU, and 2 ml normal saline.
Trial: NCT06165367
Drug: EmbryoGlue Medium
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Embryos will be exposed to hyaluronic-enriched media (EmbryoGlue) before and during embryo transfer
Trial: NCT05508789
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT06498505
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of equally looking placebo capsules in the morning and in the evening, starting 24 hours before departure to 3600 m.
Trial: NCT04999969
Drug: AZD0171
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD0171
Trial: NCT04922398
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% normal saline will be injected in each ovary
Trial: NCT06199453
Drug: Lutetium (177Lu) vipivotide tetraxetan
RxNorm normalized name: lutetium (177Lu) vipivotide tetraxetan
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6 cycles of lutetium (177Lu) vipivotide-tetraxetan with an activity of 200 mCi (7.4 GBq) at intervals of 6 weeks
Trial: NCT06079281
Drug: ALXN1850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALXN1850 will be administered via subcutaneous (SC) injection.
Trial: NCT06079281
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered via SC injection.
Trial: NCT06249945
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo tablet is manufactured by Prince Pharmaceutical Co., Ltd, a leading manufacturer of nutritional supplements with certifications including cGMP, GMP, ISO, and HACCP. The Prince Pharmaceutical also provides Original Equipment Manufacturing (OEM)/Original Design Manufacturing (ODM) services for a wide array of tablet shapes, and post-processing techniques such as film coating and sugar coating.
Trial: NCT06484075
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo will be a tablet, but only containing inert inactive ingredients.
Trial: NCT06616532
Drug: PM8002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following a predefined dose and date.
Trial: NCT05722002
Drug: Opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once randomized to this group the surgical team will elect for 1 of the following treatment options to be given:~* Oxycodone 5 mg by mouth every four to six hours as needed for pain, 10 doses~* Morphine 7.5 mg by mouth every four to six hours as needed for pain, 10 doses~* Hydromorphone 2 mg by mouth every four to six hours as needed for pain, 10 doses
Trial: NCT05722002
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 1000 mg by mouth every 6 hours around the clock for the first three days after surgery then as needed thereafter (20 doses).
Trial: NCT06584071
Drug: PM8002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PM8002 via IV infusion, Q3W
Trial: NCT06584071
Drug: PM1009
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PM8002 via IV infusion, Q3W
Trial: NCT06191978
Drug: ASTX727
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by PO
Trial: NCT06465641
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microcrystalline cellulose in capsules
Trial: NCT05010954
Drug: LXI-15028 50mg group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigational products are administrated orally, once in the morning every day, and each dose includes 2 tablets of investigational products (LXI-15028 50mg active agent + Lansoprazole 30mg matching placebo). If the investigational product is not taken in the morning, subjects can take it before 6:00 p.m. on the same day. The duration of treatment is 4 or 6 weeks
Trial: NCT06053580
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily for 24 weeks.
Trial: NCT04989413
Drug: Placebo oral drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: use of placebo for 12 weeks
Trial: NCT05358717
Drug: PTC518
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTC518 will be administered per dose and schedule specified in the arm.
Trial: NCT05128773
Drug: Amcenestrant-matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet, oral
Trial: NCT05358717
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to PTC518 will be administered per schedule specified in the arm.
Trial: NCT06501989
Drug: Biweekly 5-FLUOROURACIL (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU 2400 mg/m². Infusion for 46 hours. Leucovorin 200 mg/m². Either a vascular endothelial growth factor (VEGF) inhibitor or epidermal growth factor (EGFR) inhibitor or may be added to the regimen at the discretion of the treating physician. Repeat every 2 weeks.
Trial: NCT06501989
Drug: Biweekly Modified FOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin 85 mg/m². 5-FU 400 mg/m² on day 1 as bolus (OPTIONAL). 5-FU 2400 mg/m² Infusion for 46 hours. Leucovorin 200 mg/m2. Repeat every 2 weeks
Trial: NCT06501989
Drug: Biweekly FOLFIRI
RxNorm normalized name: Biweekly Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan 180 mg/m2. 5-FU 400 mg/m2 on day 1 as bolus (OPTIONAL). 5-FU 2400 mg/m2 Infusion for 46 hours. Leucovorin 200 mg/m2.~Repeat every 2 weeks.
Trial: NCT06501989
Drug: mFOLFOXIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan 165 mg/m2. Oxaliplatin 85 mg/m2. 5-FU 2400 mg/m2 Infusion for 46 hours. Repeat every 2 weeks.
Trial: NCT05507554
Drug: Opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: intravenous injection Tramadol 50 mg and then oral capsule Tramadol 50 mg, once patient starts taking orally.~Designated coated 14 days supply of pain medication (oral capsule Tramadol 50 mg) will be given to the patients on discharge. For Pain control oral capsule Tramadol 50 mg is administered 2 times per day until the stent will be removed in clinic 2 weeks later.
Trial: NCT05507554
Drug: Non-Opioid Analgesic
RxNorm normalized name: Non-opioid analgesic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: intravenous injection Paracetamol 1 Gram and then oral Tablet Paracetamol 1 Gram, once patient starts taking orally.~Designated coated 14 days supply of pain medication (oral Tablet Paracetamol 1 Gram) will be given to the patients on discharge. For Pain control oral Paracetamol 1 Gram is administered 3 times per day until the stent will be removed in clinic 2 weeks later.
Trial: NCT05849090
Drug: Cephalosporin or clindamycin/vancomycin antibiotics..
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics: Cephalosporin, 2-grams, intravenous (IV), or clindamycin (900mg) / vancomycin (20mg/kg), intravenous (IV).
Trial: NCT05849090
Drug: Vancomycin and Tobramycin antibiotics.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin (1 gram) and tobramycin (1.2 grams).
Trial: NCT05954078
Drug: mFOLFOX6/XELOX adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 12 cycles or XELOX (oxaliplatin 130mg/m2, ivgtt, Q3w; capecitabine 1000mg/m2, p.o, Q3w) for 8 cycles
Trial: NCT05483439
Drug: cytotoxic chemotherapy (docetaxel or epirubicin or cyclophosphamide or carboplatin)
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: cytotoxic chemotherapy (docetaxel or epirubicin or cyclophosphamide or carboplatin)
Trial: NCT05483439
Drug: traditional herbal medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: traditional herbal medicine
Trial: NCT06539273
Drug: Exosome Complex, RNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A total of 3 mL of exosomes (2 mL to the frontal and 1 mL to the vertex region) was injected using napage technique (10¹⁰ extracellular vesicles in 1 mL)
Trial: NCT04481555
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prophylactic azithromycin treatment 250 mg three times weekly vs placebo
Trial: NCT04481555
Drug: ICS
RxNorm normalized name: ICSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive LABA/LAMA medication. The ICS medication will be switched on/off according to the most recent blood eosinophil count (at inclusion + every 3 months) vs continued LABA/LAMA/ICS treatment
Trial: NCT04826185
Drug: IMB-1018972
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified release (MR) oral tablet
Trial: NCT04826185
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching oral tablet
Trial: NCT05536752
Drug: QA102/Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules
Trial: NCT05536752
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules